21:20 , Apr 28, 2017 |  BioCentury  |  Finance

A different animal?

For the second time, macro factors will make it hard to divine how much impact, if any, a clinical failure at Circassia Pharmaceuticals plc will have on investor sentiment in the U.K. But at least...
07:00 , Jun 27, 2016 |  BioCentury  |  Finance

Nine lives?

Whether Circassia Pharmaceuticals plc's implosion will have a lasting effect on the U.K. biotech sector is going to be hard to tease out now that the Brexit has thrown London and the global markets into...
07:00 , Jun 23, 2016 |  BC Innovations  |  Tools & Techniques

Home is in the placenta

Many drug developers have avoided stepping into what they see as the high risk area of pregnancy-associated complications, leaving diseases such as preeclampsia and fetal growth restriction with little innovation and few treatment options. By...
07:00 , Aug 21, 2014 |  BC Innovations  |  Cover Story

Fat chance for cancer cachexia

With no drugs on the market and a pair of recent Phase III failures in cancer-associated cachexia, companies could be better off turning to the cause of the wasting disease rather than targeting its symptoms....
07:00 , Mar 17, 2014 |  BioCentury  |  Finance

Circassia raises expectations

The largest-ever European biotech IPO - by Circassia Pharmaceuticals plc - plus three new filings have buysiders thinking the crack in a European IPO window could be widening. But if Circassia doesn't perform, it could...
07:00 , Oct 7, 2013 |  BioCentury  |  Finance

4Q Financial Markets Preview: Room to grow - for now

Even as biotech indices surpass all-time highs, investors are saying there is more room to run. While buysiders and bankers do expect the pace of growth to slow in the coming year, they think the...
07:00 , May 27, 2013 |  BioCentury  |  Finance

Demand disequilibrium

BioCentury's 11th annual European Iceberg survey sees funding demand continue to fall for a shrinking number of public clinical-stage biotechs in Europe, while the capital demanded by the growing cadre of venture biotechs continues to...
08:00 , Feb 25, 2013 |  BC Week In Review  |  Financial News

Ark Therapeutics financial update

The Wellcome Trust (London, U.K.) sold 7.7 million Ark Therapeutics common shares representing less than a 3% stake. The shares are valued at £56,546 ($87,629) based on Ark's close of 0.73p on Feb. 20, the...
08:00 , Feb 4, 2013 |  BC Week In Review  |  Company News

Ark Therapeutics supply/service news

Ark said it has retained WG Partners to evaluate strategic options, including a long-term partnership "which may include an offer" for the company. In January, Ark said it had received "insufficient" support from shareholders for...
07:00 , Aug 20, 2012 |  BC Week In Review  |  Company News

Ark Therapeutics, Merck KGaA deal

Ark Therapeutics and Merck's EMD Millipore Corp. division signed a non-binding letter of intent to partner for manufacturing of viral-based bioengineered vaccines and live viral products. The deal covers the optimization of vaccine production for...